Summary:
- Teva Pharmaceuticals presented post-hoc clinical data for TEV-749, an investigational once-monthly subcutaneous injectable of olanzapine designed for the treatment of schizophrenia.
- The study results demonstrate high rates of patient stabilization and sustained long-term efficacy, supporting the potential of this formulation to improve medication adherence and clinical outcomes for adults living with schizophrenia.